Clinical trials have shown promising results with a combination of bevacizumab, a monoclonal antibody that inhibits VEGF, and the EGFR inhibitor erlotinib, that blocks these two important pathways in cancer growth [17]. The gene discussed is EGFR; the disease is cancer.